Tifcemalimab

Product Description: Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer[1].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Jun M, et, al. Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas. Blood (2022) 140 (Supplement 1): 3716–3717.

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: CD28

• SKU: MEXHY-P99961-5
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-P99961-5
• Package Unit: 5 mg
• Quantity Unit: STK
• Conjugate: Unconjugated